DOCSLIB.ORG

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release March 24, 2009 / Vol. 58 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Summary ...............................................................................................1 Control and Prevention (CDC), U.S. Department of Health and Introduction ...........................................................................................2 Human Services, Atlanta, GA 30333. History of the Guidelines .........................................................................2 Guidelines Process .................................................................................2 Suggested Citation: Centers for Disease Control and Prevention. Major Changes in Guidelines Since Last Publication ..................................3 [Title]. MMWR Early Release 2009;58[Date]:[inclusive page numbers]. How to Use the Information in this Report .................................................3 Centers for Disease Control and Prevention Effect of ART on the Management of OIs ..................................................4 Julie L. Gerberding, MD, MPH Initiation of ART in the Setting of an Acute OI Director (Treatment-Naïve Patients) .....................................................................4 Management of Acute OIs in Patients Receiving ART .................................5 Tanja Popovic, MD, PhD Chief Science Officer Special Considerations During Pregnancy ................................................5 Disease Specific Recommendations ..........................................................6 James W. Stephens, PhD Pneumocystis Pneumonia .....................................................................6 Associate Director for Science Toxoplasma gondii Encephalitis ..........................................................10 Steven L. Solomon, MD Cryptosporidiosis ..............................................................................14 Director, Coordinating Center for Health Information and Service Microsporidiosis ................................................................................17 Jay M. Bernhardt, PhD, MPH Mycobacterium tuberculosis Infection and Disease ...............................19 Director, National Center for Health Marketing Disseminated Mycobacterium avium Complex Disease .........................28 Katherine L. Daniel, PhD Bacterial Respiratory Disease .............................................................31 Deputy Director, National Center for Health Marketing Bacterial Enteric Infections ..................................................................36 Bartonellosis .....................................................................................39 Editorial and Production Staff Syphilis ............................................................................................41 Frederic E. Shaw, MD, JD Mucocutaneous Candidiasis ...............................................................45 Editor, MMWR Series Cryptococcosis ..................................................................................48 Susan F. Davis, MD Histoplasmosis ..................................................................................50 (Acting) Assistant Editor, MMWR Series Coccidioidomycosis ...........................................................................52 Teresa F. Rutledge Aspergillosis .....................................................................................54 Managing Editor, MMWR Series Cytomegalovirus Disease ...................................................................55 Herpes Simplex Virus Disease ............................................................61 David C. Johnson HHV-6 and HHV-7 Disease ................................................................63 (Acting) Lead Technical Writer-Editor Varicella-Zoster Virus Diseases ...........................................................64 Suzanne M. Hewitt, MPA Human Herpesvirus-8 Disease ............................................................66 Project Editor Human Papillomavirus Disease ...........................................................68 Martha F. Boyd Hepatitis B Virus Infection ..................................................................75 Lead Visual Information Specialist Hepatitis C Virus Infection ..................................................................84 Malbea A. LaPete Progressive Multifocal Leukoencephalopathy/JC Virus Infection .................91 Stephen R. Spriggs Geographic OIs of Specific Consideration ..............................................94 Visual Information Specialists Malaria ............................................................................................94 Kim L. Bright, MBA Penicilliosis marneffei ........................................................................98 Quang M. Doan, MBA Leishmaniasis ....................................................................................99 Phyllis H. King Chagas Disease .............................................................................103 Information Technology Specialists Isosporiasis .....................................................................................105 Editorial Board References .........................................................................................107 Tables ................................................................................................145 William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Figures ..............................................................................................197 Virginia A. Caine, MD, Indianapolis, IN Appendix ..........................................................................................199 David W. Fleming, MD, Seattle, WA List of Abbreviations Used in this Report ...............................................204 William E. Halperin, MD, DrPH, MPH, Newark, NJ Contributors .......................................................................................206 Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA Disclosure of Relationship John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI CDC, our planners, and our content specialists wish to disclose they have no finan- cial interests or other relationships with the manufacturers of commercial products, Sue Mallonee, MPH, Oklahoma City, OK suppliers of commercial services, or commercial supporters, with the exception of Patricia Quinlisk, MD, MPH, Des Moines, IA Constance Benson and King K. Holmes. Dr. Benson discloses being on the Advisory Patrick L. Remington, MD, MPH, Madison, WI Board for Merck, GlaxoSmithKline, and Boehringer Ingelheim; being a grant Barbara K. Rimer, DrPH, Chapel Hill, NC recipient for Gilead; and being a Data Safety Monitoring Board (DSMB) member John V. Rullan, MD, MPH, San Juan, PR for Achillion and JJR Australia. Her spouse also is a consultant for Merck, Gilead, William Schaffner, MD, Nashville, TN Achillion, Monogram, and Vertex. Dr. Holmes discloses being a DSMB member of Anne Schuchat, MD, Atlanta, GA Merck, receiving an honorarium at the 2005 Infectious Diseases Society of America Dixie E. Snider, MD, MPH, Atlanta, GA Conference, and serving on the Mycology Research Laboratories scientific advisory John W. Ward, MD, Atlanta, GA board. Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use. Vol. 58 Early Release 1 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Prepared by Jonathan E. Kaplan, MD1 Constance Benson, MD2 King K. Holmes, MD, PhD3 John T. Brooks, MD1 Alice Pau, PharmD4 Henry Masur, MD4 1CDC, Atlanta, Georgia 2 University of California San Diego, San Diego, California 3University of Washington, Seattle, Washington 4National Institutes of Health, Bethesda, Maryland Summary This report updates and combines earlier versions of guidelines for the prevention and treatment of opportunistic infections (OIs) in HIV-infected adults (i.e., persons aged >18 years) and adolescents (i.e., persons aged 13–17 years), last published in 2002 and 2004, respectively. It has been prepared by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by clinicians and other health-care providers, HIV-infected patients, and policy makers in the United States. These guidelines address several OIs that occur in the United States and five OIs that might be acquired during international travel. Topic areas covered for each OI include epidemiology, clinical manifestations, diagnosis, prevention of exposure; prevention of disease by chemoprophylaxis and vac- cination; discontinuation of primary prophylaxis after immune reconstitution; treatment of disease; monitoring for adverse effects
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine Et Al
    US00899.3581B2 (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine et al. (45) Date of Patent: Mar. 31, 2015 (54) METHODS FOR TREATINGVIRAL (58) Field of Classification Search DSORDERS CPC ... A61K 31/00; A61K 31/166; A61K 31/185: A61K 31/233; A61K 31/522: A61K 38/12: (71) Applicant: Trustees of Boston University, Boston, A61K 38/15: A61K 45/06 MA (US) USPC ........... 514/263.38, 21.1, 557, 565, 575, 617; 424/2011 (72) Inventors: Susan Perrine, Weston, MA (US); Douglas Faller, Weston, MA (US) See application file for complete search history. (73) Assignee: Trustees of Boston University, Boston, (56) References Cited MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 3,471,513 A 10, 1969 Chinn et al. patent is extended or adjusted under 35 3,904,612 A 9/1975 Nagasawa et al. U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/915,092 FOREIGN PATENT DOCUMENTS (22) Filed: Jun. 11, 2013 CA 1209037 A 8, 1986 CA 2303268 A1 4f1995 (65) Prior Publication Data (Continued) US 2014/OO45774 A1 Feb. 13, 2014 OTHER PUBLICATIONS Related U.S. Application Data (63) Continuation of application No. 12/890,042, filed on PCT/US 10/59584 Search Report and Written Opinion mailed Feb. Sep. 24, 2010, now abandoned. 11, 2011. (Continued) (60) Provisional application No. 61/245,529, filed on Sep. 24, 2009, provisional application No. 61/295,663, filed on Jan. 15, 2010. Primary Examiner — Savitha Rao (74) Attorney, Agent, or Firm — Nixon Peabody LLP (51) Int.
    [Show full text]
  • Impact of HIV on Gastroenterology/Hepatology
    Core Curriculum: Impact of HIV on Gastroenterology/Hepatology AshutoshAshutosh Barve,Barve, M.D.,M.D., Ph.D.Ph.D. Gastroenterology/HepatologyGastroenterology/Hepatology FellowFellow UniversityUniversityUniversity ofofof LouisvilleLouisville Louisville Case 4848 yearyear oldold manman presentspresents withwith aa historyhistory ofof :: dysphagiadysphagia odynophagiaodynophagia weightweight lossloss EGDEGD waswas donedone toto evaluateevaluate thethe problemproblem University of Louisville Case – EGD Report ExtensivelyExtensively scarredscarred esophagealesophageal mucosamucosa withwith mucosalmucosal bridging.bridging. DistalDistal esophagealesophageal nodulesnodules withwithUniversity superficialsuperficial ulcerationulceration of Louisville Case – Esophageal Nodule Biopsy InflammatoryInflammatory lesionlesion withwith ulceratedulcerated mucosamucosa SpecialSpecial stainsstains forfor fungifungi revealreveal nonnon-- septateseptate branchingbranching hyphaehyphae consistentconsistent withwith MUCORMUCOR University of Louisville Case TheThe patientpatient waswas HIVHIV positivepositive !!!! University of Louisville HAART (Highly Active Anti Retroviral Therapy) HIV/AIDS Before HAART After HAART University of Louisville HIV/AIDS BeforeBefore HAARTHAART AfterAfter HAARTHAART ImmuneImmune dysfunctiondysfunction ImmuneImmune reconstitutionreconstitution OpportunisticOpportunistic InfectionsInfections ManagementManagement ofof chronicchronic ¾ Prevention diseasesdiseases e.g.e.g. HepatitisHepatitis CC ¾ Management CirrhosisCirrhosis NeoplasmsNeoplasms
    [Show full text]
  • Recognizing and Treating New and Emerging Infections Encountered in Everyday Practice
    Recognizing and treating new and emerging infections encountered in everyday practice STEVEN M. GORDON, MD NFECTIOUS DISEASES, pre- MiikWirj:« Although infectious diseases were once considered a dicted earlier in this cen- diminishing threat, new pathogens are constantly challenging tury to be eliminated as a the health care system. This article reviews the clinical presen- public health problem, re- tation, diagnosis, and treatment of seven emerging infections I main the chief cause of death that primary care physicians are likely to encounter. worldwide and a significant cause of death and morbidity in i Parvovirus B19 attacks erythrocyte precursors; the United States.1 Challenging infection is usually benign and self-limiting but can cause the US public health system are aplastic crises in patients with chronic hemolytic disorders. several newly identified patho- Hemorrhagic colitis due to Escherichia coli 0157:H7 infection gens (eg, human immunodefi- can lead to the hemolytic-uremic syndrome, especially in chil- ciency virus [HIV], Escherichia dren; it also can cause thrombotic thrombocytopenia purpura. coli 0157:H7, hepatitis C) and a Chlamydia pneumoniae causes a mild pneumonia that resem- resurgence of old diseases pre- bles mycoplasmal pneumonia. Bacillary angiomatosis primar- sumed to be under control (eg, ily affects immunocompromised patients, especially those tuberculosis, syphilis). Further, infected with human immunodeficiency virus (HIV). At least multiple-drug resistance in two organisms can cause bacillary angiomatosis: Bartonella hense- strains of pneumococci, gono- lae and Bartonella quintana. Hantavirus pulmonary syndrome cocci, enterococci, staphylo- is spread by exposure to the droppings of infected rodents. cocci, salmonella, and mycobac- Contrary to previous thought, HIV continues to replicate teria undermines efforts to throughout the course of the illness and does not have a latency control the diseases they cause.2 phase.
    [Show full text]
  • Idiopathic CD4 Lymphocytopenia: Spectrum of Opportunistic Infections, Malignancies, and Autoimmune Diseases
    Published online: 2021-08-09 REVIEW ARTICLE Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases Dina S. Ahmad, Mohammad Esmadi, William C. Steinmann Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, USA Access this article online ABSTRACT Website: www.avicennajmed.com DOI: 10.4103/2231-0770.114121 Idiopathic CD4 lymphocytopenia (ICL) was first defined in 1992 by the US Centers for Disease Quick Response Code: Control and Prevention (CDC) as the repeated presence of a CD4+ T lymphocyte count of fewer than 300 cells per cubic millimeter or of less than 20% of total T cells with no evidence of human immunodeficiency virus (HIV) infection and no condition that might cause depressed CD4 counts. Most of our knowledge about ICL comes from scattered case reports. The aim of this study was to collect comprehensive data from the previously published cases to understand the characteristics of this rare condition. We searched the PubMed database and Science Direct for case reports since 1989 for Idiopathic CD4 lymphocytopenia cases. We found 258 cases diagnosed with ICL in 143 published papers. We collected data about age, sex, pathogens, site of infections, CD4 count, CD8 count, CD4:CD8 ratio, presence of HIV risk factors, malignancies, autoimmune diseases and whether the patients survived or died. The mean age at diagnosis of first opportunistic infection (or ICL if no opportunistic infection reported) was 40.7 ± 19.2 years (standard deviation), with a range of 1 to 85. One-sixty (62%) patients were males, 91 (35.2%) were females, and 7 (2.7%) patients were not identified whether males or females.
    [Show full text]
  • Bacterial Superinfection of Influenza Protein-2 Expression Drives Illness in Dysregulated Macrophage-Inflammatory
    Dysregulated Macrophage-Inflammatory Protein-2 Expression Drives Illness in Bacterial Superinfection of Influenza This information is current as Caleb C. J. Zavitz, Carla M. T. Bauer, Gordon J. Gaschler, of October 3, 2021. Katie M. Fraser, Robert M. Strieter, Cory M. Hogaboam and Martin R. Stampfli J Immunol published online 11 January 2010 http://www.jimmunol.org/content/early/2010/01/11/jimmun ol.0903304 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/01/11/jimmunol.090330 Material 4.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 3, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 11, 2010, doi:10.4049/jimmunol.0903304 The Journal of Immunology Dysregulated Macrophage-Inflammatory Protein-2 Expression Drives Illness in Bacterial Superinfection of Influenza Caleb C. J. Zavitz,* Carla M. T. Bauer,* Gordon J. Gaschler,* Katie M. Fraser,† Robert M. Strieter,‡ Cory M. Hogaboam,x and Martin R. Stampfli†,{ Influenza virus infection is a leading cause of death and disability throughout the world.
    [Show full text]
  • The Impact of Infection During Pregnancy on the Mother and Baby
    16 The Impact of Infection During Pregnancy on the Mother and Baby Heather E. Jeffery and Monica M. Lahra Infection continues to account for a major pro- ascending infection from the lower genital tract, portion of maternal, fetal, and neonatal mortality and perinatal acquisition, which includes nos- and morbidity worldwide. ocomial infection and transmission of infection In the developing world, maternal systemic via breast milk (maternal or banked milk). infections, such as pneumonia, malaria, tubercu- The impact of infection (bacterial, viral, or losis, typhoid fever, and pyelonephritis, which are other) on the mother or the fetus is dependent often functions of poverty, crowding, and malnu- on maternal and fetal factors in addition to the trition, impose health costs to the mother and pathogenic properties of the infecting agent. risks to the fetus. These risks include spontaneous Maternal factors include immune function and abortion, stillbirth, preterm labor and preterm status, anatomical factors, and comorbidity. birth, low birth weight, intrauterine growth Infecting agent factors include dose, exposure, restriction (IUGR), and infection. This is in addi- and individual virulence factors. Fetal factors tion to the rapidly escalating rates of a number of include gestational age, developmental stage, and sexually transmitted diseases, in particular, fetal immune function. Table 16.1 summarizes human immunodefi ciency virus (HIV) infection the potential impact on the fetus and neonate with its associated comorbidities. with respect to the ante-, peri-, and postnatal In the developed world, preterm birth remains periods. a major, unresolved public health issue. Intrauter- The impact of infection in pregnancy on both ine infection has been shown to play a major role mother and baby is discussed in this chapter.
    [Show full text]
  • Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents
    Morbidity and Mortality Weekly Report Recommendations and Reports December 17, 2004 / Vol. 53 / No. RR-15 Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America INSIDE: Continuing Education Examination department of health and human services Centers for Disease Control and Prevention MMWR CONTENTS The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Introduction......................................................................... 1 Control and Prevention (CDC), U.S. Department of How To Use the Information in This Report .......................... 2 Health and Human Services, Atlanta, GA 30333. Effect of Antiretroviral Therapy on the Incidence and Management of OIs .................................................... 2 SUGGESTED CITATION Initiation of ART in the Setting of an Acute OI Centers for Disease Control and Prevention. Treating (Treatment-Naïve Patients) ................................................. 3 Management of Acute OIs in the Setting of ART .................. 4 opportunistic infections among HIV-infected adults and When To Initiate ART in the Setting of an OI ........................ 4 adolescents: recommendations from CDC, the National Special Considerations During Pregnancy ........................... 4 Institutes of Health, and the HIV Medicine Association/ Disease Specific Recommendations ....................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Food Safety Labelling of Chicken to Prevent Campylobacteriosis: Consumer Expectations and Current Practices Philip D
    Allan et al. BMC Public Health (2018) 18:414 https://doi.org/10.1186/s12889-018-5322-z RESEARCH ARTICLE Open Access Food safety labelling of chicken to prevent campylobacteriosis: consumer expectations and current practices Philip D. Allan†, Chloe Palmer†, Fiona Chan, Rebecca Lyons, Olivia Nicholson, Mitchell Rose, Simon Hales and Michael G. Baker* Abstract Background: Campylobacter is the leading cause of bacterial gastroenteritis worldwide, and contaminated chicken is a significant vehicle for spread of the disease. This study aimed to assess consumers’ knowledge of safe chicken handling practices and whether their expectations for food safety labelling of chicken are met, as a strategy to prevent campylobacteriosis. Methods: We conducted a cross-sectional survey of 401 shoppers at supermarkets and butcheries in Wellington, New Zealand, and a systematic assessment of content and display features of chicken labels. Results: While 89% of participants bought, prepared or cooked chicken, only 15% knew that most (60–90%) fresh chicken in New Zealand is contaminated by Campylobacter. Safety and correct preparation information on chicken labels, was rated ‘very necessary’ or ‘essential’ by the majority of respondents. Supermarket chicken labels scored poorly for the quality of their food safety information with an average of 1.7/5 (95% CI, 1.4–2.1) for content and 1.8/ 5 (95% CI, 1.6–2.0) for display. Conclusions: Most consumers are unaware of the level of Campylobacter contamination on fresh chicken and there is a significant but unmet consumer demand for information on safe chicken preparation on labels. Labels on fresh chicken products are a potentially valuable but underused tool for campylobacteriosis prevention in New Zealand.
    [Show full text]
  • WHO Technical Consultation to Review the Role of Drugs in Malaria Prevention for People Living in Endemic Settings
    Malaria Policy Advisory Committee Meeting 13—14 May 2020, Geneva, Switzerland Background document for Session 5 WHO technical consultation to review the role of drugs in malaria prevention for people living in endemic settings Meeting report, 16–17 October 2019, Geneva, Switzerland Summary On 16–17 October 2019, the World Health Organization (WHO) convened a Technical Consultation to review the use of medicines for malaria prevention in endemic countries and to identify opportunities to increase their impact through review of the flexibility of the recommendations for their deployment. Experts reviewed the policies and use of chemoprevention as currently endorsed by WHO, including intermittent preventive treatment in pregnancy (IPTp), intermittent preventive treatment in infants (IPTi), seasonal malaria chemoprevention (SMC) and mass drug administration (MDA) for the reduction of disease burden in emergency situations. By reviewing these strategies side-by-side for the first time, the meeting was able to consider opportunities for optimization. Additional potential applications of chemoprevention were also reviewed, and key considerations identified to develop a broader role for malaria chemoprevention in malaria-endemic populations. Key conclusions of the meeting included: • There is a need for general guidance on the broader use of chemoprevention. Chemoprevention is an important approach in the package of strategies that countries may use to decrease their malaria burden and/or move towards malaria elimination. Development of broader, more flexible guidance that builds on existing chemoprevention recommendations in specific populations is expected to support the greater, more rational use of chemoprevention and enhance its impact. • Chemoprevention strategies may be tailored to country-specific needs. Guidance should be flexible enough to enable adaptation of strategies according to the needs of different countries and settings.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]